


02-1601

99A11653\$
WDBOK 840

Please type a plus sign (+) inside this box → ☐

PTO/SB/29 (12/97)



**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**

Submit an original, and a duplicate for fee processing.

CHECK BOX, if applicable:
☐ DUPLICATE

(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No.	X-10242
	First Named Inventor	R. Hermeling, et al.
	Express Mail Label No.	EL018701539US

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/209,799 filed on December 11, 1998, entitled GLUCAGON-LIKE PEPTIDE-1 CRYSTALS

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the same as a request required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

RECEIVED

- ☐ Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application.
- ☒ A preliminary amendment is enclosed.
- This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
 - ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:
 - ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
- ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
- Information Disclosure Statement (IDS) is enclosed:
 - ☒ PTO-1449
 - ☒ Copies of IDS Citations

FEB 21 2001

TECH CENTER 1600/2900

RECEIVED

FEB 26 2001

TECH CENTER 1600/2900

01 03 22 03 19
005070141
005070141

Please type a plus sign (+) inside this box →

+

PTO/SB/29 (12/97)

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c))		9-20 =		x\$ 18.00=	\$
INDEPENDENT CLAIMS (37 CFR 1.16(b))		2- 3 =		x\$ 80.00=	
MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))				+\$ _____ =	
				BASIC FEE (37 CFR 1.16(a))	\$ 710.00
				Total of above Calculations=	\$
				Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).	
				TOTAL =	\$710.00

6. Small entity status:

a. ☐ A small entity statement is enclosed.

b. ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.

c. ☐ Is no longer claimed.

7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 05-0840:

a. ☒ Fees required under 37 CFR 1.16.

b. ☐ Fees required under 37 CFR 1.17.

c. ☐ Fees required under 37 CFR 1.18.

8. ☐ A check in the amount of \$ _____ is enclosed.

9. ☐ Other: _____

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

10. NEW CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label	(Insert Customer No. Or Attach bar code label here)	or	Correspondence address below
NAME	Mark J. Stewart, Ph.D.		
ADDRESS	Eli Lilly and Company		
	Lilly Corporate Center		
	Patent Division DC: 1104		
CITY	Indianapolis	STATE	Indiana
COUNTRY	U.S.A.	TELEPHONE	317-276-0280
		FAX	317-276-3861
11. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
NAME	Mark J. Stewart, Ph.D.		
SIGNATURE	<i>Mark J. Stewart</i>		
DATE	February 15, 2001		
"Express Mail" mailing label number <u>EL018701539US</u> Date of Deposit <u>February 15, 2001</u> I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231. <u>Olga M. Frank</u> Printed Name <u>Olga M. Frank</u> Signature			